drugset / Trial / NCT01122108
Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale
Phase 4
Completed
42 enrolled
Louisville Metabolic and Atherosclerosis Research Center
Daiichi Sankyo · collabProvident Clinical Research · collab
RandomizedCrossoverSingle-blindTreatment
Summary
The objective of this study is to compare the acceptability of Colesevelam HCl powder for oral suspension versus generic cholestyramine via the BASA scale, based upon an anticipated equivalent cholesterol lowering doses of each comparator drug.
Timeline
- Start
- 2010-04
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cholestyramine | Other / unclassified | 12 g | — |
| Comparator | Colesevelam | Other / unclassified | 4 g | Oral |
Indications
No indication recorded.